Interestingly, immunological studies revealed that C19-A3-tolDC vaccine was able to control autoimmunity, after 6 months, in three patients exhibiting pre-existing vaccine peptide response by reducing antigen-specific proliferation and interferon-gamma (IFN-γ) production or increasing IL-10 secretion. Here, IFNG is linked to Autoimmunity.